Indivumed and University of Rochester Join Forces for Cancer Research

Indivumed and the University of Rochester Medical Center (URMC) are expanding their collaboration to enhance patient-centric cancer research. This partnership aims to accelerate the discovery of novel therapeutics for cancer patients with significant medical needs. The announcement was made on December 10, 2025, in Hamburg, Germany, and Rochester, New York.

The collaboration leverages Indivumed’s established methodologies in standardized tissue and clinical data collection. This approach focuses on patient-centric research and drug development, utilizing high-quality biosamples and clinical data processed according to rigorous standard operating procedures (SOPs). The collaboration emphasizes minimizing ischemia time to under ten minutes, which is crucial for maintaining sample integrity.

Aims of the Collaboration

A primary objective of this partnership is the creation of well-characterized, patient-derived tumor models (PDTMs). These models, including classical cell cultures, spheroids, and organoids, will help in identifying and validating pharmaceutical molecular targets. Insights gained from this research will significantly advance the development of targeted cancer therapies.

Hartmut Land, PhD, Deputy Director of the Wilmot Cancer Institute, expressed optimism about the collaboration, stating, “We have worked with Indivumed successfully in the past, and our familiarity with their tissue and multi-omics data approach will provide an excellent foundation.” He believes that this project will enhance the identification of new therapeutics and biomarkers, which are essential for improving clinical decision-making in cancer care.

The initial focus of this partnership will be on advanced stages of solid cancers, including colorectal cancer (CRC), pancreatic cancer (PDAC), lung cancer, and breast cancer. There is potential for expanding research to include other cancer types in the future. This collaboration not only aims to drive Indivumed’s research initiatives but also provides valuable insights for clinicians regarding therapeutic decision-making.

Significance of the Partnership

In discussing the partnership, Hartmut Juhl, CEO and founder of Indivumed, remarked, “We are thrilled to deepen our collaboration with URMC, significantly enhancing our ability to identify novel cancer therapeutics in a truly patient-centered approach.” He emphasized the commitment to developing primary tumor models to test new compounds against targets identified through Indivumed’s AI-powered data analytics.

With this agreement, URMC joins the Indivumed Global Clinical Network, which includes several renowned hospitals and leading oncology institutes across North America, Europe, and Asia. This collaboration builds on prior successful research efforts, including a recent publication that explored new methods for classifying distinct types of colon cancer.

The Wilmot Cancer Institute, part of the University of Rochester Medical Center, is recognized as an NCI-Designated Cancer Center. It serves a diverse population of over three million people across 27 counties in New York, leading in cancer care and research. The institute employs more than 190 oncology physicians and 500-plus oncology nurses, supported by approximately 115 scientists dedicated to investigating various aspects of cancer.

Indivumed, a biotech company focused on precision oncology, aims to redefine cancer treatment through the discovery of novel therapeutic targets. With over two decades of experience, Indivumed is committed to advancing cancer care by ensuring that every patient benefits from precise therapeutic options.

For further inquiries, please contact:
Kristin Maack, VP Corporate Communications, Indivumed, [email protected]
Kellie Fraver, Strategic Communications Director, University of Rochester Medical Center, [email protected], +1-585-314-1552.